Pacira Pharma (PCRX): Guidance Weaker Than Expected - Wedbush

November 3, 2016 8:11 AM EDT
Get Alerts PCRX Hot Sheet
Price: $39.50 --0%

Rating Summary:
    11 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 16 | New: 50
Trade PCRX Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) but cut her price target to $89 from $93 after Q3 EXPAREL sales were in-line and 2016 EXPAREL guidance slightly reduced to $263-268MM (from $270-$280MM).

Q3 EXPAREL sales of $64.9MM were in line with consensus estimate of $65MM. The analyst offered insight into the seasonality of elective surgery though, noting that "Q3 is usually a seasonally weak qtr for EXPAREL sales as surgeons and patients go on summer vacation. Q4 tends to be the strongest quarter from Q3 delays and because patients use up their flex spending accounts."

The GAAP EPS (loss) of $(0.59) came in lower than consensus of $(0.15) due to a $29MM one-time charge to COGS due to a batch of EXPAREL that did not meet required specifications. Pacira ended Q3 with ~$161MM in cash and eq.

The next significant catalyst is the release of October Symphony Health EXPAREL sales estimate on Nov 23.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $33.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Earnings

Related Entities

Liana Moussatos

Add Your Comment